The total value of all payments for the Atacand brand is $400m
News
NICE collaboration creates new route for medicines approval
New Innovative Licensing and Access Pathway launched
Pfizer’s Lorbrena scores US priority review
Drug is being reviewed for ALK-positive lung cancer
CRUK scientists develop drug that targets KRAS pathways
KRAS mutations are found in several hard-to-treat cancers
Janssen files EGFR-targeting antibody amivantamab with EMA
Submission based on results from phase I CHRYSALIS study
AstraZeneca/Oxford University’s COVID-19 vaccine set for UK rollout
Shot was approved by MHRA on 30 December
Ridgeback Biotherapeutics’ Ebola treatment scores FDA approval
Ebanga approved to treat Ebola in adult and paediatric patients
Amgen files KRAS inhibitor sotorasib with EMA
Submission supported by results from phase II CodeBreaK 100 study
AMO Pharma launches late-stage study of CMD candidate
REACH-CDM study was based on results of positive phase II data
Vicore Pharma’s C21 med shows promise in COVID-19 study
Drug is being studied in hospitalised COVID-19 patients
EU green light for Zogenix’s Fintepla
Oral solution approved to treat seizures associated with Dravet syndrome
Shionogi’s novel antibiotic added to UK’s pilot subscription reimbursement model
Payment for drug linked to value to NHS rather than volume used
MHRA approves Polyphor’s phase 1 trial of novel inhaled antibiotic
Murepavadin is being developed to treat Pseudomonas aeruginosa infections in people with cystic fibrosis
EU nod for first long-acting HIV injectable treatment
Rekambys plus Vocabria authorised to treat HIV-1 infections in adults who are virologically suppressed
AZ, Amgen’s SOURCE trial misses primary endpoint
New medicine tezepelumab is being studied in severe asthma
